Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 19, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2025

Conditions

Metastatic Malignant Melanoma

Interventions

DRUG

Pembrolizumab

200 mg IV every 3 weeks

DRUG

Carboplatin

AUC=6, every 3 weeks x 4

DRUG

Paclitaxel

175 mg/m2, every 3 weeks x 4

Trial Locations (2)

Jewish General Hospital, Montreal

Hopital Notre-Dame, Montreal

All Listed Sponsors

lead

Wilson Miller

OTHER